Physician profile
Jagmeet Singh
NPI 1902179666
$14,565.22
in general payments reported to CMS, 2019-2025
16 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.95 · 2020: $37.58 · 2021: $4,562 · 2022: $2,216 · 2023: $368 · 2024: $7,031 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,900 · Food and Beverage: $679 · Travel and Lodging: $60.41 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,900.00 |
| Food and Beverage | $679.22 |
| Travel and Lodging | $60.41 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,060.41 | 2022-2024 | Accent |
| Merit Medical Systems INC | $4,400.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $246.75 | 2021-2023 | Lokelma, Farxiga |
| Amgen INC. | $206.42 | 2019-2025 | Tavneos |
| Ardelyx, INC. | $120.20 | 2025 | Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $108.03 | 2023-2025 | Velphoro, Velphoro, Korsuva |
| Janssen Pharmaceuticals, INC | $81.22 | 2020-2021 | |
| Vifor Pharma, INC. | $76.15 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $64.25 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $57.36 | 2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $54.06 | 2023 | Acthar |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Kyowa Kirin, INC. | $17.30 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $14.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagmeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.